Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550191 | 0.76 | — | — | |
| SCHEMBL1823076 | 0.75 | — | — | |
| SCHEMBL25547088 | 0.72 | — | — | |
| SCHEMBL9558258 | 0.72 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL9558301 | 0.71 | NPC1 (0.35) | SLC6A3MAPTALDH1A1KMT2A | |
| SCHEMBL21158801 | 0.69 | CASP3 (0.38) | SLC6A3MAPTALDH1A1HTTKMT2A | |
| SCHEMBL3017954 | 0.69 | SLC6A3 (0.37) | SLC6A3ALDH1A1 | |
| SCHEMBL2302986 | 0.69 | — | — | |
| SCHEMBL27666384 | 0.68 | HTR2A (0.38) | SLC6A3ALDH1A1 | |
| SCHEMBL472521 | 0.68 | SLC6A3 (0.36) | SLC6A3MAPTALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412716-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2012-02-01 | — | — | EP | claimed |
| CN-101827847-A | Purine derivatives as adenosine al receptor ligands | NOVARTIS AG | 2010-09-08 | — | — | CN | claimed |
| EP-1476455-A1 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003070739-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-8927521-B2 | Cyclic adenosine monophosphates for reducing the formation of adhesions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-01-06 | — | — | US | disclosed |
| CN-101827847-A | Purine derivatives as adenosine al receptor ligands | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
| WO-2010054068-A2 | CYCLIC ADENOSINE MONOPHOSPHATES FOR REDUCING THE FORMATION OF ADHESIONS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-05-14 | — | — | WO | disclosed |
| CN-1671728-A | Novel adenosine analogues and their use as pharmaceutical agents | AVENTIS PHARMA GMBH (DE) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | SLC6A3 2027/4885MAPT 4512/4885ALDH1A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.